OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
The OSPREY Patient Registry has been developed to collect and assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry. The Registry data will provide both complementary and contemporary information to the existing clinical data across various countries and will form part of the post-market clinical follow-up activities for OncoSil™. Therefore, the Registry will be implemented only in countries with regulatory (commercial) approval for the OncoSil™ device.
Patients with confirmed unresectable locally advanced pancreatic cancer (LAPC). [+7]
Patient Informed Consent Form (PICF) has not been completed and signed for the O... [+10]